The US healthcare CDMO market is estimated to grow significantly during the forecast period. The major factors that are projected to contribute to the growth of the market include the presence of contract manufacturers in the US that has significantly minimized costs and reduce product development time. Moreover, the growing demand for generic drugs, the rising number of drug development processes, and the emergence of several new market players in the pharmaceutical industry are some other crucial factors that are propelling the market in the US.
The US market for healthcare CDMO is segregated on the basis of services and region. Based on services, the market is further classified into contract development and contract manufacturing. The contract manufacturing services segment is projected to have a significant share in the US healthcare CDMO market owing to the significant adoption of outsourcing services by pharmaceutical companies across the globe. The contract development services are further classified into clinical, preclinical, and laboratory services. The clinical segment is projected to have significant growth in the market owing to increasing clinical research. Moreover, the contract manufacturing services segment is further classified into API, finished dosage formulations, and medical devices. The API contract manufacturing services segment is significantly contributing to the growth of the market during the forecast period.
The companies which are contributing to the growth of the US healthcare CDMO market include AbbVie Inc., Baxter International, Inc., Catalent, Inc., Pfizer Inc., Thermo Fisher Scientific Inc., Jabil Inc., and others. Product launch, merger, and acquisition, collaborations with government, and technological advancements through which market players are considerably contributing to the market growth to stay competitive in the market. For instance, in May 2019, Catalent, Inc. completed the acquisition of Paragon Bioservices, Inc., a contract research and manufacturing organization, for $1.2 billion. With this acquisition, paragon brought its unique development and manufacturing capabilities, which is anticipated to improve Catalent’s biologics business and projected to provide a significant presence in the market.
Research Methodology
The market study of the US healthcare CDMO market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
The report is intended for pharmaceutical and medical device companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, products offered by the companies, and future market opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.
Market Segmentation
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Market Determinants
3.1. Motivators
3.2. Restraints
3.3. Opportunities
4. Market Segmentation
4.1. US Healthcare CDMO Market by Services
4.1.1. Contract Development
4.1.1.1. Clinical
4.1.1.2. Preclinical
4.1.1.3. Laboratory Services
4.1.2. Contract Manufacturing
4.1.2.1. Active Pharmaceutical Ingredients( API)
4.1.2.2. Finish Dosage Formulations
4.1.2.3. Medical Devices
5. Company Profiles
5.1. AbbVie Inc.
5.2. Baxter International, Inc.
5.3. Catalent Inc.
5.4. Covance Inc.
5.5. Cambrex Corp.
5.6. Hisun Pharmaceuticals Inc.
5.7. Jabil Inc.
5.8. Pfizer Inc.
5.9. Stason Pharmaceuticals, Inc.
5.10. Thermo Fisher Scientific Inc.
1. US HEALTHCARE CDMO MARKET RESEARCH AND ANALYSIS BY SERVICES, 2019-2026 ($ MILLION)
1. US HEALTHCARE CDMO MARKET SHARE BY SERVICES, 2019 VS 2026 (%)
2. US HEALTHCARE CDMO MARKET SIZE, 2019-2026 ($ MILLION)